Michelle E. Melisko

Michelle E. Melisko

Oncology

1825 Fourth St.
Third Floor
San Francisco, CA 94158

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 144 publications

Clinical and molecular features of resected breast cancer brain metastases: a single center retrospective cohort study.

Clinical and molecular features of resected breast cancer brain metastases: a single center retrospective cohort study.

Journal: Breast cancer research and treatment

Published: March 30, 2026

Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer.

Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer.

Journal: Clinical breast cancer

Published: March 20, 2026

Phase 2 test of QBS72S for breast cancer leptomeningeal disease.

Phase 2 test of QBS72S for breast cancer leptomeningeal disease.

Journal: Neuro-oncology

Published: March 10, 2026

Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.

Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.

Journal: Research square

Published: February 23, 2026

Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.

Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.

Journal: Research square

Published: February 23, 2026

OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.

OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.

Journal: Breast cancer research and treatment

Published: January 05, 2026

Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases.

Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases.

Journal: Breast (Edinburgh, Scotland)

Published: November 11, 2025

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.

Journal: ESMO open

Published: October 07, 2025

Detection of actionable mutations in the cerebrospinal fluid and concordance/discordance with extracranial mutations in patients with metastatic breast cancer and leptomeningeal disease.

Detection of actionable mutations in the cerebrospinal fluid and concordance/discordance with extracranial mutations in patients with metastatic breast cancer and leptomeningeal disease.

Journal: Therapeutic advances in medical oncology

Published: September 06, 2025

Evaluating survival trends over time in patients with metastatic breast cancer and brain metastases: a single center retrospective cohort study.

Evaluating survival trends over time in patients with metastatic breast cancer and brain metastases: a single center retrospective cohort study.

Journal: Breast cancer research : BCR

Published: July 16, 2025

Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer.

Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer.

Journal: NPJ breast cancer

Published: May 05, 2025

Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases.

Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases.

Journal: BMC cancer

Published: March 26, 2025

Showing 1-12 of 144

Last Updated: 09/26/2026